Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Progesterone-mediated oocyte maturation (mmu04914)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Adcy1
KLA  ATP  ATP+KLA
 BC050125 adenylate cyclase 1, mRNA (cDNA clone IMAGE:30015692). [BC050125] KLA 1.05 1.03 .98 1.04 1.05 1.09 1.10
ATP .90 1.02 .99 .97 1.03 .95 1.01
KLA/ATP .99 1.04 .90 .98 .98 1.00 1.03
Adcy1
KLA  ATP  ATP+KLA
 NM_009622 adenylate cyclase 1 (Adcy1), mRNA [NM_009622] KLA 1.07 1.02 1.06 1.07 1.03 1.02 1.01
ATP 1.02 1.04 1.00 .99 .99 .95 .97
KLA/ATP .97 1.05 1.02 1.05 1.01 .98 1.05
Adcy2
KLA  ATP  ATP+KLA
 NM_153534 adenylate cyclase 2 (Adcy2), mRNA [NM_153534] KLA .79 .82 .83 .73 .61 .66 .90
ATP 1.10 1.09 1.02 1.04 .88 .58 .53
KLA/ATP .84 .87 .77 .75 .68 .60 .43
Adcy3
KLA  ATP  ATP+KLA
 NM_138305 adenylate cyclase 3 (Adcy3), mRNA [NM_138305] KLA .84 .84 .83 .78 .66 .55 .49
ATP 1.09 1.05 .89 1.02 .84 .62 1.52
KLA/ATP .93 .87 .75 .85 .66 .83 .77
Adcy4
KLA  ATP  ATP+KLA
 NM_080435 adenylate cyclase 4 (Adcy4), mRNA [NM_080435] KLA 1.05 1.07 .96 1.00 1.04 1.05 1.05
ATP 1.02 1.05 1.02 1.48 1.37 1.08 1.09
KLA/ATP 1.00 1.05 .91 1.19 1.35 1.27 1.08
Adcy5
KLA  ATP  ATP+KLA
 NM_001012765 adenylate cyclase 5 (Adcy5), mRNA [NM_001012765] KLA 1.06 1.00 .97 1.01 1.03 .95 .93
ATP .95 1.08 1.08 1.07 .97 1.03 .97
KLA/ATP .97 .92 1.04 .99 .91 .96 1.04
Adcy6
KLA  ATP  ATP+KLA
 NM_007405 adenylate cyclase 6 (Adcy6), mRNA [NM_007405] KLA 1.10 1.16 1.16 1.09 1.08 1.06 .99
ATP 1.05 .97 1.08 1.12 1.08 1.08 1.04
KLA/ATP 1.14 1.20 1.29 1.30 1.25 1.11 1.07
Adcy7
KLA  ATP  ATP+KLA
 NM_001037724 adenylate cyclase 7 (Adcy7), transcript variant 3, mRNA [NM_001037724] KLA .43 .39 .35 .32 .45 .72 .84
ATP .90 .84 .62 .41 .53 .42 .94
KLA/ATP .39 .34 .23 .17 .41 .34 .67
Adcy7
KLA  ATP  ATP+KLA
 NM_007406 adenylate cyclase 7 (Adcy7), transcript variant 1, mRNA [NM_007406] KLA .51 .52 .48 .41 .59 .81 .99
ATP 1.01 1.02 .62 .52 .53 .38 .98
KLA/ATP .53 .48 .30 .27 .42 .36 .65
Adcy8
KLA  ATP  ATP+KLA
 NM_009623 adenylate cyclase 8 (Adcy8), mRNA [NM_009623] KLA 1.00 1.00 1.07 .97 1.04 .98 1.02
ATP 1.04 1.05 1.14 1.03 .99 1.00 .97
KLA/ATP 1.05 1.04 1.00 1.03 .98 .94 .96
Adcy9
KLA  ATP  ATP+KLA
 NM_009624 adenylate cyclase 9 (Adcy9), mRNA [NM_009624] KLA .18 .15 .13 .15 .17 .19 .33
ATP 1.33 1.16 .97 .98 .62 .56 .86
KLA/ATP .19 .16 .17 .18 .20 .25 .38
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Anapc1
KLA  ATP  ATP+KLA
 AK090134 nullipotent stem cell CRL-2070 NE cDNA, RIKEN full-length enriched library, clone:G431003J08 product:meiotic check point regulator, full insert sequence [AK090134] KLA .79 .76 .72 .64 .56 .54 .76
ATP .99 1.04 1.11 .77 .48 .31 .39
KLA/ATP .72 .75 .73 .57 .42 .30 .25
Anapc1
KLA  ATP  ATP+KLA
 NM_008569 anaphase promoting complex subunit 1 (Anapc1), mRNA [NM_008569] KLA 1.00 .89 .81 .89 .66 .75 .74
ATP .88 .79 .97 .46 .48 .93 .76
KLA/ATP .76 .77 .83 .37 .44 .74 .62
Anapc10
KLA  ATP  ATP+KLA
 NM_026904 anaphase promoting complex subunit 10 (Anapc10), mRNA [NM_026904] KLA 1.38 1.24 1.22 1.30 1.13 1.14 1.05
ATP .96 .99 1.22 1.01 .77 1.16 .94
KLA/ATP 1.19 1.24 1.50 1.23 .97 1.17 1.02
Anapc11
KLA  ATP  ATP+KLA
 NM_001038230 anaphase promoting complex subunit 11 homolog (yeast) (Anapc11), transcript variant 1, mRNA [NM_001038230] KLA .89 .90 .91 .85 .82 .78 .82
ATP 1.01 1.06 1.04 1.06 1.00 .85 .75
KLA/ATP .96 .93 .83 .96 .87 .79 .64
Anapc13
KLA  ATP  ATP+KLA
 NM_181394 anaphase promoting complex subunit 13 (Anapc13), mRNA [NM_181394] KLA .98 .96 .89 .99 .85 .91 .72
ATP .99 .95 1.22 1.25 1.23 1.07 .67
KLA/ATP .95 1.01 1.27 1.23 1.35 1.19 .76
Anapc2
KLA  ATP  ATP+KLA
 NM_175300 anaphase promoting complex subunit 2 (Anapc2), mRNA [NM_175300] KLA .90 .92 1.02 .91 1.03 .94 .81
ATP 1.08 1.16 .96 1.18 .86 .75 .94
KLA/ATP 1.04 1.07 .93 1.11 .84 .66 .89
Anapc4
KLA  ATP  ATP+KLA
 NM_024213 anaphase promoting complex subunit 4 (Anapc4), mRNA [NM_024213] KLA .94 .99 1.01 1.08 1.21 1.22 1.09
ATP .95 .91 .86 .69 .61 .89 .96
KLA/ATP .93 .95 .84 .77 .80 .96 1.00
Anapc5
KLA  ATP  ATP+KLA
 NM_021505 anaphase-promoting complex subunit 5 (Anapc5), transcript variant 1, mRNA [NM_021505] KLA .80 .82 .83 .82 .79 .84 1.10
ATP .99 .99 .89 .81 .79 .70 .71
KLA/ATP .82 .81 .72 .62 .63 .73 .68
Anapc7
KLA  ATP  ATP+KLA
 AK049968 adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630034H22 product:anaphase-promoting complex subunit 7, full insert sequence. [AK049968] KLA .89 .86 .88 .85 .91 .95 .89
ATP .92 .89 .89 .86 .96 .99 1.00
KLA/ATP .89 .79 .83 .85 .93 .92 .87
Anapc7
KLA  ATP  ATP+KLA
 NM_019805 anaphase promoting complex subunit 7 (Anapc7), mRNA [NM_019805] KLA .65 .69 .70 .79 .91 1.00 .92
ATP .96 .99 .81 .89 1.46 1.30 1.00
KLA/ATP .70 .73 .64 .72 1.14 1.28 1.04
Araf
KLA  ATP  ATP+KLA
 NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Bub1
KLA  ATP  ATP+KLA
 NM_009772 budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae) (Bub1), transcript variant 2, mRNA [NM_009772] KLA .49 .43 .34 .28 .12 .12 .11
ATP 1.11 1.16 1.30 1.36 .79 .36 .09
KLA/ATP .49 .40 .42 .41 .24 .14 .07
Ccna1
KLA  ATP  ATP+KLA
 NM_007628 cyclin A1 (Ccna1), mRNA [NM_007628] KLA .97 .96 1.03 1.01 .97 .96 1.02
ATP .98 .99 1.00 1.01 .98 .95 .98
KLA/ATP 1.05 .96 1.01 1.04 .97 .92 1.01
Ccna2
KLA  ATP  ATP+KLA
 NM_009828 cyclin A2 (Ccna2), mRNA [NM_009828] KLA .28 .21 .19 .14 .09 .07 .06
ATP 1.17 1.11 1.03 1.01 .59 .20 .05
KLA/ATP .29 .22 .23 .21 .13 .08 .06
Ccnb1
KLA  ATP  ATP+KLA
 NM_172301 cyclin B1 (Ccnb1), mRNA [NM_172301] KLA .41 .37 .34 .29 .20 .18 .12
ATP 1.05 1.04 1.22 1.33 1.02 .54 .10
KLA/ATP .44 .37 .42 .39 .37 .22 .10
Ccnb2
KLA  ATP  ATP+KLA
 NM_007630 cyclin B2 (Ccnb2), mRNA [NM_007630] KLA .60 .51 .52 .39 .25 .15 .09
ATP .99 .89 1.32 1.14 .93 .55 .10
KLA/ATP .58 .52 .70 .59 .86 .47 .15
Ccnb3
KLA  ATP  ATP+KLA
 NM_183015 cyclin B3 (Ccnb3), mRNA [NM_183015] KLA 1.00 1.04 1.09 .93 1.03 1.05 1.03
ATP 1.00 1.02 .97 1.06 1.06 1.01 1.05
KLA/ATP 1.03 .99 1.04 1.04 1.10 1.12 1.03
Cdc16
KLA  ATP  ATP+KLA
 AK012511 11 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2700071J12 product:unclassifiable, full insert sequence. [AK012511] KLA .97 .92 .89 .90 .93 .92 .99
ATP .97 .94 .89 .92 .89 .94 .91
KLA/ATP .98 .88 .99 .93 .80 .89 .82
Cdc16
KLA  ATP  ATP+KLA
 NM_027276 CDC16 cell division cycle 16 homolog (S. cerevisiae) (Cdc16), mRNA [NM_027276] KLA .96 .98 .97 .90 .89 .85 .88
ATP 1.03 1.02 1.06 .82 .70 .87 .71
KLA/ATP .96 .93 .96 .79 .68 .73 .61
Cdc23
KLA  ATP  ATP+KLA
 NM_178347 CDC23 (cell division cycle 23, yeast, homolog) (Cdc23), mRNA [NM_178347] KLA .74 .76 .75 .74 .72 .79 .79
ATP 1.06 1.04 .91 .71 .48 .60 .71
KLA/ATP .76 .77 .73 .66 .46 .51 .59
Cdc25a
KLA  ATP  ATP+KLA
 NM_007658 cell division cycle 25 homolog A (S. pombe) (Cdc25a), mRNA [NM_007658] KLA .76 .77 .75 .68 .83 1.00 .95
ATP .97 1.03 .83 .69 1.01 .84 .79
KLA/ATP .69 .71 .80 .70 .91 .81 .81
Cdc25a
KLA  ATP  ATP+KLA
 U27323 Cdc25a (cdc25a) mRNA, complete cds. [U27323] KLA .62 .60 .58 .58 .77 .87 .87
ATP 1.16 1.04 .77 .57 1.16 .74 .72
KLA/ATP .65 .64 .63 .54 .86 .68 .58
Cdc25b
KLA  ATP  ATP+KLA
 NM_023117 cell division cycle 25 homolog B (S. pombe) (Cdc25b), transcript variant 1, mRNA [NM_023117] KLA .38 .34 .33 .34 .30 .31 .26
ATP .98 1.04 1.01 .89 .67 .58 .39
KLA/ATP .36 .33 .37 .40 .51 .43 .32
Cdc25c
KLA  ATP  ATP+KLA
 NM_009860 cell division cycle 25 homolog C (S. pombe) (Cdc25c), mRNA [NM_009860] KLA .62 .63 .62 .61 .50 .49 .29
ATP .95 1.00 .97 .97 .73 .64 .28
KLA/ATP .61 .62 .61 .68 .67 .64 .32
Cdc26
KLA  ATP  ATP+KLA
 AK041840 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630041F01 product:unclassifiable, full insert sequence. [AK041840] KLA .92 .88 .95 .88 1.08 .99 1.15
ATP .72 .64 .61 .75 .91 .85 1.04
KLA/ATP .84 .75 .66 .87 .94 .95 .99
Cdc26
KLA  ATP  ATP+KLA
 NM_139291 cell division cycle 26 (Cdc26), mRNA [NM_139291] KLA 1.04 1.07 1.01 1.25 1.38 1.55 1.25
ATP .98 .97 1.06 .91 .91 1.47 1.38
KLA/ATP .88 1.02 1.24 .99 1.25 1.66 1.74
Cdc27
KLA  ATP  ATP+KLA
 NM_145436 cell division cycle 27 homolog (S. cerevisiae) (Cdc27), mRNA [NM_145436] KLA 1.36 1.25 1.22 1.07 1.05 1.06 1.00
ATP .90 .97 1.06 .84 .81 .88 .73
KLA/ATP 1.25 1.22 1.07 .87 .98 .95 .72
Cdc2a
KLA  ATP  ATP+KLA
 NM_007659 cell division cycle 2 homolog A (S. pombe) (Cdc2a), mRNA [NM_007659] KLA .72 .68 .65 .58 .58 .59 .48
ATP 1.01 1.05 1.21 1.06 .83 .77 .51
KLA/ATP .68 .63 .79 .70 .59 .59 .51
Cdk2
KLA  ATP  ATP+KLA
 NM_016756 cyclin-dependent kinase 2 (Cdk2), transcript variant 2, mRNA [NM_016756] KLA .68 .67 .62 .63 .60 .74 .73
ATP 1.02 1.14 .91 .92 .68 .71 .65
KLA/ATP .67 .64 .64 .64 .61 .74 .62
Cpeb1
KLA  ATP  ATP+KLA
 NM_007755 cytoplasmic polyadenylation element binding protein 1 (Cpeb1), mRNA [NM_007755] KLA .58 .50 .48 .45 .32 .30 .36
ATP 1.11 1.07 .89 .83 .72 .59 .47
KLA/ATP .55 .56 .67 .58 .60 .48 .26
Fzr1
KLA  ATP  ATP+KLA
 NM_019757 fizzy/cell division cycle 20 related 1 (Drosophila) (Fzr1), mRNA [NM_019757] KLA 1.08 .98 .95 1.03 1.44 1.33 .97
ATP 1.06 1.19 .93 1.16 1.05 1.21 .94
KLA/ATP 1.02 1.05 .83 1.04 .84 1.21 1.43
Gnai1
KLA  ATP  ATP+KLA
 NM_010305 guanine nucleotide binding protein (G protein), alpha inhibiting 1 (Gnai1), mRNA [NM_010305] KLA .95 1.01 1.01 1.00 1.09 1.10 1.08
ATP 1.06 1.06 .99 1.15 1.02 .94 .99
KLA/ATP 1.02 1.04 .99 1.16 1.01 1.02 1.13
Gnai2
KLA  ATP  ATP+KLA
 NM_008138 guanine nucleotide binding protein (G protein), alpha inhibiting 2 (Gnai2), mRNA [NM_008138] KLA .74 .79 .82 .74 .91 .97 1.10
ATP 1.07 1.16 .78 1.12 .78 .48 .82
KLA/ATP .91 .81 .53 .80 .60 .68 .87
Gnai3
KLA  ATP  ATP+KLA
 NM_010306 guanine nucleotide binding protein (G protein), alpha inhibiting 3 (Gnai3), mRNA [NM_010306] KLA 1.23 1.24 1.14 1.06 .99 1.15 1.09
ATP .96 .93 .86 .64 1.34 2.02 1.35
KLA/ATP 1.20 1.24 .97 .76 1.21 1.62 1.17
Hsp90aa1
KLA  ATP  ATP+KLA
 NM_010480 heat shock protein 90, alpha (cytosolic), class A member 1 (Hsp90aa1), mRNA [NM_010480] KLA .95 1.03 .90 .92 .80 .94 .99
ATP .96 .92 1.39 1.21 2.02 3.66 1.10
KLA/ATP .93 .92 1.32 1.01 1.85 2.21 1.20
Hsp90ab1
KLA  ATP  ATP+KLA
 NM_008302 heat shock protein 90kDa alpha (cytosolic), class B member 1 (Hsp90ab1), mRNA [NM_008302] KLA .93 1.02 .98 .82 .95 1.10 1.39
ATP 1.04 1.14 .92 1.32 1.19 1.02 .63
KLA/ATP 1.02 1.04 .80 1.12 .87 .86 .75
Igf1
KLA  ATP  ATP+KLA
 AK050118 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730016P09 product:unclassifiable, full insert sequence. [AK050118] KLA .13 .14 .15 .16 .22 .34 .48
ATP 1.78 2.05 1.37 .72 .34 .41 .58
KLA/ATP .24 .45 .50 .24 .20 .26 .68
Igf1
KLA  ATP  ATP+KLA
 NM_010512 insulin-like growth factor 1 (Igf1), transcript variant 1, mRNA [NM_010512] KLA .84 .78 .76 .67 .54 .48 .59
ATP .97 .98 1.13 1.13 1.03 .88 .89
KLA/ATP .82 .81 .93 .86 .83 .65 .89
Igf1
KLA  ATP  ATP+KLA
 NM_184052 insulin-like growth factor 1 (Igf1), transcript variant 2, mRNA [NM_184052] KLA .77 .82 .76 .65 .60 .52 .69
ATP 1.01 1.07 .98 1.06 1.03 .78 .94
KLA/ATP .89 .86 .77 .80 .75 .65 .89
Igf1r
KLA  ATP  ATP+KLA
 NM_010513 insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513] KLA 1.32 1.32 1.08 .91 .55 .48 .45
ATP 1.03 1.06 1.06 1.29 1.31 1.45 .47
KLA/ATP 1.30 1.37 1.11 1.00 .93 1.02 .45
Ins1
KLA  ATP  ATP+KLA
 NM_008386 insulin I (Ins1), mRNA [NM_008386] KLA 1.00 .99 .99 1.03 1.01 .98 1.06
ATP .97 1.03 1.00 1.03 .99 1.07 1.05
KLA/ATP 1.03 .93 .98 1.04 1.07 1.03 1.01
Ins2
KLA  ATP  ATP+KLA
 NM_008387 insulin II (Ins2), mRNA [NM_008387] KLA .99 1.00 1.00 1.01 1.00 1.02 1.00
ATP 1.01 .99 1.00 1.00 .98 .99 1.01
KLA/ATP .99 1.01 1.00 .98 .99 .99 .98
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Mad1l1
KLA  ATP  ATP+KLA
 NM_010752 mitotic arrest deficient 1-like 1 (Mad1l1), mRNA [NM_010752] KLA .92 .84 .84 .78 .59 .63 .61
ATP .94 .99 1.19 1.39 .78 .52 .72
KLA/ATP .87 .92 .91 .96 .68 .54 .59
Mad2l1
KLA  ATP  ATP+KLA
 NM_019499 MAD2 (mitotic arrest deficient, homolog)-like 1 (yeast) (Mad2l1), mRNA [NM_019499] KLA .70 .68 .73 .71 .52 .41 .28
ATP 1.06 1.02 1.43 1.25 1.03 .53 .19
KLA/ATP .70 .69 .99 .84 .70 .43 .18
Mad2l1
KLA  ATP  ATP+KLA
 U83902 mitotic checkpoint component Mad2 mRNA, complete cds. [U83902] KLA .67 .68 .67 .60 .50 .39 .27
ATP .95 .97 1.28 1.28 .88 .54 .19
KLA/ATP .62 .66 .84 .91 .62 .41 .18
Mad2l2
KLA  ATP  ATP+KLA
 NM_027985 MAD2 mitotic arrest deficient-like 2 (yeast) (Mad2l2), mRNA [NM_027985] KLA 1.47 1.43 1.53 1.81 1.64 1.37 1.24
ATP 1.05 .92 1.13 1.24 1.09 1.00 .85
KLA/ATP 1.47 1.50 1.78 1.50 1.75 1.58 1.05
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk10
KLA  ATP  ATP+KLA
 AK076990 adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] KLA 1.03 1.05 .98 1.04 .94 .95 1.02
ATP 1.00 .99 1.06 .97 1.01 .96 .99
KLA/ATP 1.07 1.01 .95 1.05 .82 .95 .87
Mapk10
KLA  ATP  ATP+KLA
 NM_009158 mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] KLA .95 1.00 .97 1.01 .99 1.01 .95
ATP 1.01 1.02 .98 1.01 1.04 1.01 .99
KLA/ATP 1.05 .99 1.01 .98 .92 .97 .98
Mapk11
KLA  ATP  ATP+KLA
 NM_011161 mitogen-activated protein kinase 11 (Mapk11), mRNA [NM_011161] KLA 1.28 1.30 1.41 1.46 1.58 1.29 .98
ATP .96 .95 .89 .82 .79 1.09 .85
KLA/ATP 1.44 1.42 1.32 1.23 1.23 .74 .66
Mapk12
KLA  ATP  ATP+KLA
 NM_013871 mitogen-activated protein kinase 12 (Mapk12), mRNA [NM_013871] KLA .94 .86 .87 .81 .77 .68 .49
ATP .97 .83 .92 .90 .86 .90 .51
KLA/ATP .91 .89 .88 .85 1.12 1.14 .53
Mapk13
KLA  ATP  ATP+KLA
 NM_011950 mitogen-activated protein kinase 13 (Mapk13), mRNA [NM_011950] KLA 1.22 1.21 1.35 1.26 1.24 1.13 1.01
ATP 1.08 1.00 1.20 1.20 1.13 1.22 1.39
KLA/ATP 1.22 1.27 1.30 1.30 1.21 1.11 1.47
Mapk14
KLA  ATP  ATP+KLA
 NM_011951 mitogen-activated protein kinase 14 (Mapk14), mRNA [NM_011951] KLA .70 .70 .62 .54 .67 .88 1.11
ATP 1.03 .98 .87 .69 .48 .78 .66
KLA/ATP .74 .68 .52 .46 .38 .45 .62
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mapk8
KLA  ATP  ATP+KLA
 AK162915 adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] KLA .94 .86 .80 .83 .77 .85 .83
ATP 1.08 1.12 .94 .80 .83 .71 .75
KLA/ATP .83 .81 .80 .74 .74 .75 .67
Mapk8
KLA  ATP  ATP+KLA
 AK163829 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] KLA .65 .61 .66 .70 .90 1.02 1.03
ATP .99 .94 1.68 1.44 1.75 1.84 1.10
KLA/ATP .63 .67 1.11 1.00 2.01 1.68 1.15
Mapk8
KLA  ATP  ATP+KLA
 NM_016700 mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] KLA .96 1.00 .94 .96 .94 .99 1.04
ATP 1.01 1.05 1.01 .99 1.03 .98 1.02
KLA/ATP .96 .97 .96 .97 .93 .94 .96
Mapk9
KLA  ATP  ATP+KLA
 NM_016961 mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] KLA 1.28 1.37 1.59 1.60 1.61 1.43 1.38
ATP 1.03 .99 .74 .71 .79 1.20 1.01
KLA/ATP 1.53 1.30 1.07 .99 .83 1.10 1.40
Mapk9
KLA  ATP  ATP+KLA
 NM_207692 mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] KLA 1.39 1.53 1.69 1.69 1.55 1.44 1.51
ATP .95 .92 .75 .85 .70 1.46 1.17
KLA/ATP 1.37 1.35 .99 1.18 .91 1.22 1.62
Mm.18219
3
KLA  ATP  ATP+KLA
 142389041 Unknown KLA 1.02 .95 .88 .77 .57 .48 .37
ATP .90 .88 .99 1.10 1.08 .77 .36
KLA/ATP .92 .88 1.01 1.04 1.17 .79 .32
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.22094
6
KLA  ATP  ATP+KLA
 27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.27574
2
KLA  ATP  ATP+KLA
 112983655 Unknown KLA 1.35 1.16 .94 .85 .45 .33 .31
ATP .90 .86 1.17 1.09 1.18 1.21 .38
KLA/ATP 1.12 1.22 1.19 .91 .90 .83 .33
Mm.27970
KLA  ATP  ATP+KLA
 13994135 Unknown KLA 1.06 1.11 1.16 1.07 1.11 1.08 .95
ATP 1.02 1.09 1.05 1.05 .94 1.16 1.32
KLA/ATP 1.10 1.19 1.11 1.04 1.08 1.02 1.33
Mm.41137
KLA  ATP  ATP+KLA
 148747308 Unknown KLA 1.03 1.00 .95 .92 1.04 .98 .96
ATP 1.02 .98 .98 .90 .95 .92 1.07
KLA/ATP .91 .89 1.01 .95 1.00 .96 .99
Mos
KLA  ATP  ATP+KLA
 NM_020021 Moloney sarcoma oncogene (Mos), mRNA [NM_020021] KLA 1.14 1.04 1.00 .98 1.09 .94 .98
ATP 1.00 1.01 1.03 1.05 .92 1.04 1.12
KLA/ATP .97 .96 1.04 1.03 .95 .99 1.03
Pde3a
KLA  ATP  ATP+KLA
 AK004638 adult male lung cDNA, RIKEN full-length enriched library, clone:1200007J10 product:phosphodiesterase 3A, cGMP inhibited, full insert sequence. [AK004638] KLA .96 .94 .95 1.07 1.01 1.00 1.03
ATP 1.02 .95 .96 1.07 .97 .96 1.01
KLA/ATP 1.00 1.00 1.02 .94 .98 .99 1.01
Pde3a
KLA  ATP  ATP+KLA
 AK052718 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630035A07 product:inferred: phosphodiesterase 3A, cGMP inhibited, full insert sequence. [AK052718] KLA .93 1.02 .94 1.00 .98 1.03 .96
ATP 1.03 .96 1.00 .98 1.00 1.03 1.01
KLA/ATP .98 1.06 1.08 1.03 .94 .98 .89
Pde3a
KLA  ATP  ATP+KLA
 NM_018779 phosphodiesterase 3A, cGMP inhibited (Pde3a), mRNA [NM_018779] KLA 1.01 1.09 .98 .98 .93 1.03 1.09
ATP .99 .97 1.04 1.05 .96 .96 1.06
KLA/ATP 1.06 .97 .94 1.09 1.00 1.06 .96
Pde3b
KLA  ATP  ATP+KLA
 AK044183 10 days neonate cortex cDNA, RIKEN full-length enriched library, clone:A830097M14 product:phosphodiesterase 3B, cGMP-inhibited, full insert sequence. [AK044183] KLA .98 .99 1.04 .99 .93 1.01 .96
ATP 1.08 .96 .92 .93 .93 .90 .93
KLA/ATP .97 .94 .95 .89 .92 .89 .95
Pde3b
KLA  ATP  ATP+KLA
 NM_011055 phosphodiesterase 3B, cGMP-inhibited (Pde3b), mRNA [NM_011055] KLA 1.02 1.01 .95 1.00 .88 .75 .59
ATP 1.12 1.20 1.09 1.04 .71 .95 .81
KLA/ATP .90 .92 1.00 .94 .74 .85 .93
Pgr
KLA  ATP  ATP+KLA
 AK036862 adult female vagina cDNA, RIKEN full-length enriched library, clone:9930019P03 product:PROGESTERONE RECEPTOR (PR) homolog [Mus musculus], full insert sequence. [AK036862] KLA 1.05 1.06 .93 .99 1.10 .96 .98
ATP .96 1.04 .97 .94 .97 1.04 1.05
KLA/ATP .97 .96 1.00 1.06 1.01 .99 1.00
Pgr
KLA  ATP  ATP+KLA
 NM_008829 progesterone receptor (Pgr), mRNA [NM_008829] KLA 1.00 .95 .97 1.05 .98 .96 1.05
ATP .99 1.16 1.00 .93 .95 .97 1.00
KLA/ATP 1.04 1.04 .98 1.01 1.01 1.02 1.02
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Plk1
KLA  ATP  ATP+KLA
 NM_011121 polo-like kinase 1 (Drosophila) (Plk1), mRNA [NM_011121] KLA .28 .23 .26 .20 .16 .13 .08
ATP 1.09 1.06 1.15 1.07 .71 .53 .10
KLA/ATP .42 .26 .29 .29 .32 .25 .12
Prkaca
KLA  ATP  ATP+KLA
 NM_008854 protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] KLA .71 .74 .72 .70 .72 .84 .85
ATP 1.05 .98 .89 .92 .76 .60 1.02
KLA/ATP .79 .74 .55 .65 .60 .65 .93
Prkacb
KLA  ATP  ATP+KLA
 NM_011100 protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] KLA .69 .70 .66 .58 .51 .55 .59
ATP 1.02 1.19 .97 1.01 .69 .38 .56
KLA/ATP .72 .73 .57 .62 .47 .41 .45
Prkx
KLA  ATP  ATP+KLA
 NM_016979 protein kinase, X-linked (Prkx), mRNA [NM_016979] KLA 3.61 3.79 4.67 4.66 4.85 4.19 1.43
ATP .98 .90 .63 .61 1.12 1.90 1.29
KLA/ATP 3.56 3.36 2.62 2.06 2.26 2.87 2.31
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rps6ka1
KLA  ATP  ATP+KLA
 NM_009097 ribosomal protein S6 kinase polypeptide 1 (Rps6ka1), mRNA [NM_009097] KLA .64 .65 .58 .62 .78 .94 .98
ATP .87 .85 .78 .74 .58 .68 .82
KLA/ATP .59 .52 .55 .50 .50 .63 .77
Rps6ka2
KLA  ATP  ATP+KLA
 NM_011299 ribosomal protein S6 kinase, polypeptide 2 (Rps6ka2), mRNA [NM_011299] KLA 1.67 1.69 1.70 1.29 1.50 1.32 1.40
ATP 1.02 1.02 .99 1.28 3.97 3.73 1.32
KLA/ATP 1.90 1.63 1.74 1.99 2.45 2.84 1.59
Rps6ka3
KLA  ATP  ATP+KLA
 NM_148945 ribosomal protein S6 kinase polypeptide 3 (Rps6ka3), mRNA [NM_148945] KLA 2.00 2.37 2.65 2.59 2.40 1.41 .96
ATP 1.09 1.09 1.17 1.29 1.11 1.63 1.83
KLA/ATP 2.44 2.44 2.63 3.13 1.99 1.66 2.09
Rps6ka6
KLA  ATP  ATP+KLA
 NM_025949 ribosomal protein S6 kinase polypeptide 6 (Rps6ka6), mRNA [NM_025949] KLA .98 1.03 1.06 .99 1.01 1.06 1.01
ATP .96 1.00 .97 .92 1.06 1.01 1.00
KLA/ATP .95 1.01 1.01 .97 1.00 .95 1.00
Spdyb
KLA  ATP  ATP+KLA
 NM_029048 speedy homolog B (Drosophila) (Spdyb), mRNA [NM_029048] KLA 1.02 1.01 1.01 .99 1.00 1.02 1.02
ATP .96 1.01 1.01 1.05 1.00 1.04 1.01
KLA/ATP 1.01 .99 .97 1.03 1.00 1.04 1.01